ZHONG JI LS (00767) released its interim results, reporting a loss attributable to shareholders of HKD 6.51 million, a year-on-year decrease of 48.21%.
China National Life Sciences (00767) announced its interim results for the six months ended June 30, 2026, with revenue of HK$71.526 million, representing a year-on-year increase of 49.1%. The loss attributable to shareholders was HK$6.51 million, narrowing by 48.21% compared to the previous year; loss per share was HK$0.0102.
ZHONG JI LS (00767) announced its interim results for the six months ending June 30, 2026, reporting a revenue of HKD 71.526 million, a year-on-year increase of 49.1%; a loss attributable to shareholders of HKD 6.51 million, a year-on-year decrease of 48.21%; and a loss per share of HKD 0.0102.
Related Articles
US Stock Market Move | AI chip design demand drives performance Surges Synopsys, Inc. (SNPS.US) jumps over 11% after earnings
MERDEKAGOLD-DRS (06228) announced its interim results, reporting a loss attributable to the owners of the parent company of $14.877 million, a year-on-year narrowing of 7.31%.
JINYAN KAOLIN (02693): Application for the termination of listing of domestic shares on the National Equities Exchange and Quotations.
US Stock Market Move | AI chip design demand drives performance Surges Synopsys, Inc. (SNPS.US) jumps over 11% after earnings
MERDEKAGOLD-DRS (06228) announced its interim results, reporting a loss attributable to the owners of the parent company of $14.877 million, a year-on-year narrowing of 7.31%.
JINYAN KAOLIN (02693): Application for the termination of listing of domestic shares on the National Equities Exchange and Quotations.
RECOMMEND
